Jongen, Lynn http://orcid.org/0000-0001-7618-6313
Floris, Giuseppe
Wildiers, Hans
Claessens, Frank
Richard, François
Laenen, Annouschka
Desmedt, Christine
Ardui, Jan
Punie, Kevin
Smeets, Ann
Berteloot, Patrick
Vergote, Ignace
Neven, Patrick
Funding for this research was provided by:
Funds of Friends for Cancer Research Leuven
Article History
Received: 10 April 2019
Accepted: 22 April 2019
First Online: 20 May 2019
Compliance with ethical standards
:
: Hans Wildiers received travel support from Roche and Pfizer, and his institution received consulting fees and honoraria from Roche, Astra Zeneca, Amgen, Lilly, Novartis, Abbvie, Vifor Pharma, Pfizer, Celldex therapeutics, Janssen-CILAG, TRM Oncology, PUMA Biotechnology, ORION corporation and an unrestricted research grant from Roche. Christine Desmedt received speakers fee from Roche Diagnostics for her institution. Kevin Punie received travel support from Astra Zeneca, Novartis, Pfize, Pharma Mar and Roche. His institution received research funding from Sanofi, honoraria for consulting or advisory roles from Astra Zeneca, Novartis, Pfizer, Roche and Vifor Pharma and speaker fees from Novartis and Pfizer. Ann Smeets received for her institution a grant from MSD for medication for a window of opportunity trial. Patrick Neven received speaker’s fees, consulting fees, and research support from Roche (all provided to his institute). Patrick Neven is on the advisory board of Novartis, AstraZeneca, Lilly, and Pfizer (all consulting fees are provided to his institute). Ignace Vergote is on the advisory board of: Advaxis, Inc., Eisai Inc., MSD Belgium, Roche NV, Genmab A/S, Genmab US, F. Hoffmann-La Roche Ltd, Pharmamar, Millennium Pharmaceuticals, Clovis Oncology Inc., AstraZeneca NV, Tesaro Bio GmbH, Tesaro Inc, Oncoinvent AS, and Immunogen Inc. Ignace Vergote has contracted research (via KU Leuven) of: Oncoinvent AS, and Genmab A/S – Genmab B.V. Ignace Vergote receives corporate sponsored research grants by Amgen and Roche. Ignace Vergote received travel support by: Takeda Oncology, Pharma Mar, Genmab, Roche, Astrazeneca, and Tesaro. All other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee (UHL, Belgium) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the UHL in Belgium before the study started.